{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T14:03:36Z","timestamp":1705413816310},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T00:00:00Z","timestamp":1283212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00280-010-1437-3","type":"journal-article","created":{"date-parts":[[2010,8,30]],"date-time":"2010-08-30T11:06:18Z","timestamp":1283166378000},"page":"1415-1422","source":"Crossref","is-referenced-by-count":5,"title":["Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models"],"prefix":"10.1007","volume":"67","author":[{"given":"Idoia","family":"Gamez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakesha D.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri M.","family":"Routt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Hollister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"1437_CR1","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/foc.2007.22.5.9","volume":"22","author":"W Stummer","year":"2007","unstructured":"Stummer W (2007) Mechanisms of tumor-related brain edema. Neurosurg Focus 22:E8","journal-title":"Neurosurg Focus"},{"key":"1437_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF02968569","volume":"29","author":"SW Lee","year":"2006","unstructured":"Lee SW, Kim WJ, Park JA, Choi YK, Kwon YW, Kim KW (2006) Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 29:265\u2013275","journal-title":"Arch Pharm Res"},{"key":"1437_CR3","first-page":"1352","volume":"56","author":"J Tjuvajev","year":"1996","unstructured":"Tjuvajev J, Uehara H, Desai R, Beattie B, Matei I, Zhou Y, Kreek MJ, Koutcher J, Blasberg R (1996) Corticotropin-releasing factor decreases vasogenic edema. Cancer Res 56:1352\u20131360","journal-title":"Cancer Res"},{"key":"1437_CR4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cco.0000142076.52721.b3","volume":"16","author":"EC Kaal","year":"2004","unstructured":"Kaal EC, Vecht CJ (2004) The management of brain edema in brain tumors. Curr Opin Oncol 16:593\u2013600","journal-title":"Curr Opin Oncol"},{"key":"1437_CR5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1043-2760(02)00670-7","volume":"13","author":"DK Grammatopoulos","year":"2002","unstructured":"Grammatopoulos DK, Chrousos GP (2002) Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13:436\u2013444","journal-title":"Trends Endocrinol Metab"},{"key":"1437_CR6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/er.2005-0034","volume":"27","author":"EW Hillhouse","year":"2006","unstructured":"Hillhouse EW, Grammatopoulos OK (2006) The molecular mechanisms underlying the regulation of the biological activity of corticotropin releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27:260\u2013286","journal-title":"Endocr Rev"},{"key":"1437_CR7","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/jc.2002-021853","volume":"88","author":"JC Reubi","year":"2003","unstructured":"Reubi JC, Waser W, Vale W, Rivier J (2003) Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88:3312\u20133320","journal-title":"J Clin Endocrinol Metab"},{"key":"1437_CR8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1050-1738(02)00214-1","volume":"13","author":"TL Bale","year":"2003","unstructured":"Bale TL, Giordano FJ, Vale WW (2003) A new role for corticotrophin-releasing factor receptor-2: suppression of vascularization. Trends Cardiovasc Med 13:68\u201371","journal-title":"Trends Cardiovasc Med"},{"key":"1437_CR9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/07357900701788106","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G, Li S (2008) Urocortin\u2019s inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26:359\u2013368","journal-title":"Cancer Invest"},{"key":"1437_CR10","first-page":"1625","volume":"37","author":"BM Kenyon","year":"1996","unstructured":"Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D\u2019Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophtalmol Vis Sci 37:1625\u20131632","journal-title":"Invest Ophtalmol Vis Sci"},{"key":"1437_CR11","doi-asserted-by":"crossref","unstructured":"Recht LD, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milsted R, O\u2019Connor PC, Ryan RP, Wong ET (2009) A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema. J Clin Oncol 27:abstr 2078","DOI":"10.1200\/jco.2009.27.15_suppl.2078"},{"key":"1437_CR12","doi-asserted-by":"crossref","unstructured":"Mechtler L, Wong ET, Hormigo A, Pannullo S, Hines V, Milsted R, O\u2019Connor PO, Ryan RP, Recht L (2009) A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors. J Clin Oncol 27:abstr 2079","DOI":"10.1200\/jco.2009.27.15_suppl.2079"},{"key":"1437_CR13","doi-asserted-by":"crossref","unstructured":"Shapiro WR, Mechtler L, Cher L, Wheeler H, Hines V, Milsted R, O\u2019Connor PC, Ryan RP, L. Recht L (2009) A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema. J Clin Oncol 27:abstr 2080","DOI":"10.1200\/jco.2009.27.15_suppl.2080"},{"key":"1437_CR14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1517\/13543780903190689","volume":"18","author":"JA Moliterno","year":"2009","unstructured":"Moliterno JA, Henry E, Pannullo SC (2009) Corticorelin acetate injections for the treatment of peritumoral brain edema. Expert Opin Investig Drugs 18:1413\u20131419","journal-title":"Expert Opin Investig Drugs"},{"key":"1437_CR15","unstructured":"Ryan R, Moroz M, Berestein T, Evans-Freke S, Gamez I, Hines V, and Blasberg R (2009) Corticorelin acetate exhibits preclinical antitumor activity against the human glioma U87 xenograft. Proc Am Assoc Cancer Res, abstr 2326"},{"key":"1437_CR16","unstructured":"Gamez I, Ryan R, and Keir S (2010) Corticorelin acetate exhibits preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. Proc Am Assoc Cancer Res, abstr 1557"},{"issue":"5","key":"1437_CR17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/11317600-000000000-00000","volume":"23","author":"JY Hsu","year":"2009","unstructured":"Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23(5):289\u2013304","journal-title":"BioDrugs"},{"key":"1437_CR18","doi-asserted-by":"crossref","DOI":"10.1007\/0-387-29150-4","volume-title":"Survival analysis: a self-learning text","author":"DG Kleinbaum","year":"2005","unstructured":"Kleinbaum DG, Klein M (2005) Survival analysis: a self-learning text, 2nd edn. Spring, Statistics for Biology and Health, New York","edition":"2"},{"key":"1437_CR19","volume-title":"Biostatistical analysis","author":"JH Zar","year":"1999","unstructured":"Zar JH (1999) Biostatistical analysis, 4th edn. Prentice-Hall, Upper Saddle River","edition":"4"},{"key":"1437_CR20","first-page":"2279","volume":"27","author":"B Higgins","year":"2007","unstructured":"Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C, Dugan U, Heimbrook D, Packman K (2007) Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 27:2279\u20132287","journal-title":"Anticancer Res"},{"key":"1437_CR21","first-page":"241","volume":"22","author":"M Yanagisawa","year":"2009","unstructured":"Yanagisawa M, Fujimoto-Ouchi K, Yorozu K, Yamashita Y, Mori K (2009) Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. Oncol Rep 22:241\u2013247","journal-title":"Oncol Rep"},{"key":"1437_CR22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","volume":"65","author":"HP Gerber","year":"2005","unstructured":"Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671\u2013680","journal-title":"Cancer Res"},{"key":"1437_CR23","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI117857","volume":"95","author":"RS Warren","year":"1995","unstructured":"Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789\u20131797","journal-title":"J Clin Invest"},{"key":"1437_CR24","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841\u2013844","journal-title":"Nature"},{"key":"1437_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/019262339902700104","volume":"27","author":"J Mordenti","year":"1999","unstructured":"Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N (1999) Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27:14\u201321","journal-title":"Toxicol Pathol"},{"key":"1437_CR26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archopht.126.7.953","volume":"126","author":"SY Lee","year":"2008","unstructured":"Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH (2008) Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol 126:953\u2013958","journal-title":"Arch Ophthalmol"},{"key":"1437_CR27","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1073\/pnas.0712366105","volume":"105","author":"Z Hao","year":"2008","unstructured":"Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ (2008) Urocortin 2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 105:3939\u20133944","journal-title":"Proc Natl Acad Sci USA"},{"key":"1437_CR28","first-page":"1","volume":"12","author":"J Tjuvajev","year":"1998","unstructured":"Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, Matei C, Koutcher J, Kreek MJ, Blasberg R (1998) Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 12:1\u201310","journal-title":"In Vivo"},{"key":"1437_CR29","unstructured":"Investigator\u2019s Brochure Xerecept\u00ae (Corticorelin acetate): Version 1.0 Celtic Pharma Development Services Inc., New York"},{"key":"1437_CR30","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1172\/JCI111890","volume":"75","author":"HM Schulte","year":"1985","unstructured":"Schulte HM, Chrousos GP, Gold PW, Booth JD, Oldfield EH, Cutler GB Jr, Loriaux DL (1985) Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. J Clin Invest 75:1781\u20131785","journal-title":"J Clin Invest"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1437-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1437-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1437-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T02:07:28Z","timestamp":1685758048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1437-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1437"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1437-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}